Johnson & Johnson (NYSE:JNJ) announced a quarterly dividend on Monday, July 15th, RTT News reports. Stockholders of record on Tuesday, August 27th will be given a dividend of 0.95 per share on Tuesday, September 10th. This represents a $3.80 annualized dividend and a dividend yield of 2.98%. The ex-dividend date is Monday, August 26th.
Johnson & Johnson has raised its dividend payment by an average of 6.3% annually over the last three years and has raised its dividend every year for the last 56 years. Johnson & Johnson has a dividend payout ratio of 46.7% indicating that its dividend is sufficiently covered by earnings. Analysts expect Johnson & Johnson to earn $9.09 per share next year, which means the company should continue to be able to cover its $3.80 annual dividend with an expected future payout ratio of 41.8%.
JNJ opened at $127.73 on Friday. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. The company’s 50 day simple moving average is $132.65 and its 200-day simple moving average is $136.53. The stock has a market capitalization of $346.44 billion, a P/E ratio of 15.61, a price-to-earnings-growth ratio of 2.22 and a beta of 0.69.
In other Johnson & Johnson news, Director Marillyn A. Hewson acquired 3,000 shares of Johnson & Johnson stock in a transaction on Tuesday, June 11th. The shares were purchased at an average cost of $139.68 per share, with a total value of $419,040.00. Following the completion of the purchase, the director now owns 3,000 shares in the company, valued at $419,040. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.23% of the stock is currently owned by company insiders.
A number of brokerages have issued reports on JNJ. Credit Suisse Group set a $156.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Thursday, July 18th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price objective on the stock. in a research note on Thursday, July 18th. Barclays began coverage on shares of Johnson & Johnson in a research note on Friday, June 21st. They issued a “hold” rating and a $140.00 price objective on the stock. Goldman Sachs Group began coverage on shares of Johnson & Johnson in a research note on Tuesday, May 28th. They issued a “buy” rating on the stock. Finally, Raymond James reduced their price objective on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 17th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $148.56.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: Why is the price target of stocks important?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.